Raptor Pharmaceutical Corp. to Present

Raptor Pharmaceutical Corp. to Present at the 2012 Wells
Fargo Securities Healthcare Conference

essowner.com/wp-content/uploads/2012/06/jpg1″ alt=”” width=”226″ height=”76″ /> Raptor PharmaceuticalCorp. (“Raptor” or the “Company”) (Nasdaq:RPTP), today announced that
Christopher M. Starr, Ph.D., Chief Executive Officer of Raptor, will
present an overview of the Company at the 2012 Wells Fargo Securities
Healthcare Conference in Boston, MA at the InterContinental Hotel.

Presentation will take place on Tuesday, June 19, 2012
beginning at 3:30 p.m ET.

A live audio webcast and 14-day archive of the Wells Fargo presentation
will be available at http://ir.raptorpharma.com/events.cfm

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. (Nasdaq:RPTP) (“Raptor”) seeks to research,
produce, and deliver medicines that improve life for patients with
severe, rare disorders. Raptor currently has product candidates in
clinical development designed to potentially treat nephropathic
cystinosis, Non-alcoholic Steatohepatitis (“NASH”), Huntington's
Disease (“HD”), aldehyde dehydrogenase deficiency (“ALDH2″), and
thrombotic disorder.

Raptor's preclinical programs are based upon bioengineered novel drug
candidates and drug-targeting platforms derived from the human
receptor-associated protein and related proteins that are designed to
target cancer and infectious diseases.

For additional information, please visit .